Hologic, Inc. (NASDAQ:HOLX) Shares Purchased by Cerity Partners LLC

Cerity Partners LLC increased its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 50.6% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 59,884 shares of the medical equipment provider’s stock after purchasing an additional 20,132 shares during the period. Cerity Partners LLC’s holdings in Hologic were worth $4,878,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Black Creek Investment Management Inc. lifted its stake in shares of Hologic by 60.9% in the 2nd quarter. Black Creek Investment Management Inc. now owns 2,338,970 shares of the medical equipment provider’s stock valued at $173,669,000 after purchasing an additional 885,524 shares during the last quarter. Mackenzie Financial Corp boosted its stake in Hologic by 1,023.3% during the second quarter. Mackenzie Financial Corp now owns 895,699 shares of the medical equipment provider’s stock worth $66,506,000 after buying an additional 815,960 shares during the period. Marshall Wace LLP acquired a new stake in shares of Hologic during the second quarter valued at about $39,427,000. The Manufacturers Life Insurance Company raised its stake in shares of Hologic by 21.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 2,535,258 shares of the medical equipment provider’s stock valued at $188,243,000 after acquiring an additional 450,190 shares during the period. Finally, Swedbank AB raised its stake in shares of Hologic by 18.8% in the 3rd quarter. Swedbank AB now owns 1,937,002 shares of the medical equipment provider’s stock valued at $157,788,000 after acquiring an additional 306,562 shares during the period. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the stock. UBS Group lifted their target price on shares of Hologic from $84.00 to $90.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. Raymond James boosted their price objective on Hologic from $93.00 to $95.00 and gave the company an “outperform” rating in a report on Tuesday, November 5th. Citigroup cut Hologic from a “buy” rating to a “neutral” rating and lowered their target price for the company from $95.00 to $85.00 in a report on Tuesday, October 1st. Royal Bank of Canada boosted their price target on shares of Hologic from $86.00 to $89.00 and gave the stock a “sector perform” rating in a research note on Tuesday, November 5th. Finally, StockNews.com raised shares of Hologic from a “hold” rating to a “buy” rating in a research note on Thursday, November 14th. Four investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $89.91.

Hologic Stock Performance

Shares of HOLX stock opened at $79.44 on Friday. The company has a market cap of $18.45 billion, a P/E ratio of 23.86, a PEG ratio of 2.51 and a beta of 0.98. The firm has a fifty day moving average price of $80.28 and a 200 day moving average price of $78.42. The company has a current ratio of 3.69, a quick ratio of 3.03 and a debt-to-equity ratio of 0.49. Hologic, Inc. has a 12 month low of $67.59 and a 12 month high of $84.67.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.01. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The business had revenue of $987.90 million during the quarter, compared to analysts’ expectations of $978.25 million. During the same period in the prior year, the firm posted $0.89 EPS. The business’s quarterly revenue was up 4.5% compared to the same quarter last year. Sell-side analysts predict that Hologic, Inc. will post 4.27 earnings per share for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.